$0.41
7.98% day before yesterday
Nasdaq, Nov 07, 09:59 pm CET
ISIN
US92243A2006
Symbol
VXRT

Vaxart, Inc. Stock price

$0.41
+0.06 15.95% 1M
+0.02 4.71% 6M
-0.26 38.53% YTD
-0.32 43.67% 1Y
-1.02 71.54% 3Y
-3.09 88.37% 5Y
-21.81 98.17% 10Y
-87.38 99.54% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.03 7.19%
ISIN
US92243A2006
Symbol
VXRT
Industry

Key metrics

Basic
Market capitalization
$86.9m
Enterprise Value
$48.7m
Net debt
positive
Cash
$41.9m
Shares outstanding
228.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.8 | 1.4
EV/Sales
1.0 | 0.8
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
35.4%
Return on Equity
-113.6%
ROCE
-95.2%
ROIC
-169.2%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$47.4m | $63.0m
EBITDA
$-48.2m | -
EBIT
$-57.2m | $-71.4m
Net Income
$-58.1m | $-65.3m
Free Cash Flow
$-33.7m
Growth (TTM | estimate)
Revenue
433.2% | 119.4%
EBITDA
34.0% | -
EBIT
30.2% | -7.8%
Net Income
28.9% | 2.4%
Free Cash Flow
50.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-101.8% | -
EBIT
-120.6%
Net
-122.6% | -103.8%
Free Cash Flow
-71.2%
More
EPS
$-0.3
FCF per Share
$-0.1
Short interest
9.4%
Employees
105
Rev per Employee
$270.0k
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vaxart, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Vaxart, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
47 47
433% 433%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
20% 20%
39%
- Research and Development Expense 86 86
27% 27%
181%
-48 -48
34% 34%
-102%
- Depreciation and Amortization 8.92 8.92
2% 2%
19%
EBIT (Operating Income) EBIT -57 -57
30% 30%
-121%
Net Profit -58 -58
29% 29%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m.
Neutral
PRNewsWire
4 days ago
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors authorizes new $100 million share repurchase program  Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's n...
Neutral
PRNewsWire
4 days ago
Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continue leading and funding development through Phase 2b completion and End of Phase 2 meeting with FDA ; Dynavax to receive exclusive, worldwide license and right to assume responsibility for continued ...
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 105
Founded 2004
Website vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today